Biological staging of Alzheimer’s disease with the novel plasma eMTBR‐tau243 and % p ‐tau217

Abstract

Background: Given recent advancements in clinical trials and disease‐modifying treatments, the development of scalable, low‐invasive methods for staging biological Alzheimer’s disease (AD) is an urgent need. Current plasma biomarkers lack the specificity required for accurately assessing the advanced stages of AD.

The paper